Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study

被引：0
|
作者：
Kato, T. [1 ]
Kotani, D. [2 ]
Takashima, A. [3 ]
Satoh, T. [4 ]
Masuishi, T. [5 ]
Komatsu, Y. [6 ]
Shiozawa, M. [7 ]
Esaki, T.
Izawa, N. [8 ]
Takeuchi, S. [9 ]
Bando, H. [10 ]
Iwasa, S. [11 ]
Hasegawa, H. [12 ]
Yamaguchi, T. [13 ]
Taniguchi, H. [5 ]
Yamada, S. [14 ]
Yoshino, T. [2 ]
机构：
[1] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Japan
[3] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo, Japan
[4] Kinki Univ, Dept Med Oncol, Sch Med, Osaka, Japan
[5] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan
[6] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan
[7] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan
[8] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Japan
[9] Kanazawa Univ Hosp, Kanazawa, Japan
[10] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Onc, Kashiwa, Japan
[11] Natl Canc Ctr, Tokyo, Japan
[12] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan
[13] Osaka Med & Pharmaceut Univ Hosp, Takatsuki, Japan
[14] Ono Pharmaceut, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-23
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [41] Clinical research progress on BRAF V600E-mutant advanced colorectal cancer
    Chuanxiu Zeng
    Mengchao Wang
    Shuqi Xie
    Na Wang
    Zhen Wang
    Dan Yi
    Fanming Kong
    Liwei Chen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16111 - 16121
  • [42] A Phase Ib/II Study of WNT974+Encorafenib plus Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Garralda, Elena
    Tai, David
    De Braud, Filippo
    Geva, Ravit
    van Bussel, Mark T. J.
    Fiorella Dotti, Katia
    Elez, Elena
    de Miguel, Maria J.
    Litwiler, Kevin
    Murphy, Danielle
    Edwards, Michelle
    Morris, Van Karlyle
    ONCOLOGIST, 2023, : 230 - 238
  • [43] Pancreatitis After Treatment With Encorafenib, Binimetinib, and Cetuximab for BRAF V600E Mutation-Positive Colorectal Cancer
    Kureyama, Yuika
    Hanaoka, Yutaka
    Tomita, Daisuke
    Matoba, Shuichiro
    Kuroyanagi, Hiroya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [44] Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
    Trouiller, Jean-Baptiste
    Macabeo, Berengere
    Poll, Andrew
    Howard, Dan
    Buckland, Andy
    Sivignon, Marine
    Clay, Emilie
    Malka, David
    Samalin, Emmanuelle
    Toumi, Mondher
    Laramee, Philippe
    BMJ OPEN, 2022, 12 (11):
  • [45] Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study
    Desai, Jayesh
    Kopetz, Scott
    Murphy, Danielle A.
    Pu, Jie
    Ciardiello, Fortunato
    Grothey, Axel
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yaeger, Rona
    Yoshino, Takayuki
    Chantrill, Lorraine
    Tebbutt, Niall
    Strickland, Andrew
    Price, Timothy
    Karapetis, Chris
    Murphy, Felicity
    Donahue, Amber C.
    Golden, Adele
    Gollerkeri, Ashwin
    Zhu, Zhou
    Tabernero, Josep
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 89 - 89
  • [46] Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
    Wang, Xicheng
    Deng, Yanhong
    Zhang, Yanqiao
    Liu, Tianshu
    Yuan, Xianglin
    Yang, Jianwei
    Zhang, Tao
    Zang, Ai-min
    Liu, Yu
    Huang, Li
    Ye, Feng
    Zong, Hong
    Ba, Yi
    Klauck, Isabelle
    Vedovato, Jean-Claude
    Groc, Melanie
    Guo, Angela
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3559 - LBA3559
  • [47] A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)
    Kobayashi, S.
    Bando, H.
    Taketomi, A.
    Takamoto, T.
    Shinozaki, E.
    Shiozawa, M.
    Hara, H.
    Yamazaki, K.
    Komori, K.
    Matsuhashi, N.
    Kato, T.
    Kagawa, Y.
    Yokota, M.
    Oki, E.
    Takahashi, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S736 - S737
  • [48] Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study
    Sakata, Hidenori
    Murase, Maki
    Kato, Takeshi
    Yamaguchi, Kensei
    Sugihara, Kenichi
    Suzuki, Shigenobu
    Yoshino, Takayuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 139 - 144
  • [49] BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
    Huijberts, S.
    Schellens, J. H. M.
    Elez, E.
    Cuyle, P-J.
    Van Cutsem, E.
    Yaeger, R.
    Fakih, M.
    Montagut, C.
    Peeters, M.
    Desai, J.
    Yoshino, T.
    Ciardiello, F.
    Wasan, H.
    Grothey, A.
    Maharry, K.
    Gollerkeri, A.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
    Hidenori Sakata
    Maki Murase
    Takeshi Kato
    Kensei Yamaguchi
    Kenichi Sugihara
    Shigenobu Suzuki
    Takayuki Yoshino
    International Journal of Clinical Oncology, 2023, 28 : 139 - 144
12345